EP300 and cystic fibrosis: The results suggest that increasing CFTR expression using dCas9-p300 may improve the efficacy of therapeutic modulators and contribute to the discovery of new therapeutic interventions for the treatment of cystic fibrosis (CF) (56); The dCas9-p300 platform is a powerful tool for studying acetylation modifications in biological processes, and some investigators have used dCas9-p300 or dCas9-HDAC8 fusion proteins to mimic or block acetylation induced by Fos gene enhancer activity to study how histone acetylation regulates Fos gene transcription through transient and rapid changes.